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Abstract
Introduction: Sepsis is a complex immunological response to infection characterized by early hyper-inflammation
followed by severe and protracted immunosuppression, suggesting that a multi-marker approach has the greatest
clinical utility for early detection, within a clinical environment focused on Systemic Inflammatory Response
Syndrome (SIRS) differentiation. Pre-clinical research using an equine sepsis model identified a panel of gene
expression biomarkers that define the early aberrant immune activation. Thus, the primary objective was to apply
these gene expression biomarkers to distinguish patients with sepsis from those who had undergone major open
surgery and had clinical outcomes consistent with systemic inflammation due to physical trauma and wound
healing.
Methods: This was a multi-centre, prospective clinical trial conducted across four tertiary critical care settings in
Australia. Sepsis patients were recruited if they met the 1992 Consensus Statement criteria and had clinical
evidence of systemic infection based on microbiology diagnoses (n = 27). Participants in the post-surgical (PS)
group were recruited pre-operatively and blood samples collected within 24 hours following surgery (n = 38).
Healthy controls (HC) included hospital staff with no known concurrent illnesses (n = 20). Each participant had
minimally 5 ml of PAXgene blood collected for leucocyte RNA isolation and gene expression analyses. Affymetrix
array and multiplex tandem (MT)-PCR studies were conducted to evaluate transcriptional profiles in circulating
white blood cells applying a set of 42 molecular markers that had been identified a priori. A LogitBoost algorithm
was used to create a machine learning diagnostic rule to predict sepsis outcomes.
Results: Based on preliminary microarray analyses comparing HC and sepsis groups, a panel of 42-gene expression
markers were identified that represented key innate and adaptive immune function, cell cycling, WBC
differentiation, extracellular remodelling and immune modulation pathways. Comparisons against GEO data
confirmed the definitive separation of the sepsis cohort. Quantitative PCR results suggest the capacity for this test
to differentiate severe systemic inflammation from HC is 92%. The area under the curve (AUC) receiver operator
characteristics (ROC) curve findings demonstrated sepsis prediction within a mixed inflammatory population, was
between 86 and 92%.
Conclusions: This novel molecular biomarker test has a clinically relevant sensitivity and specificity profile, and has
the capacity for early detection of sepsis via the monitoring of critical care patients.
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Systemic Inflammatory Response Syndrome (SIRS) is an
overwhelming whole body reaction that may have an
infectious or non-infectious aetiology and is described in
association with critical conditions that include, but are
not limited to, pancreatitis, ischemia, trauma and severe
tissue injury, including that encountered in patients hav-
ing major surgery. Major open surgery is a controlled
form of physical insult that results in varying degrees of
systemic inflammation. To date, it has been reported
that the occurrence of SIRS following cardiac bypass
surgery [1,2], is common, as well as being a major cause
of postoperative complications including death. In parti-
cular, Michalopoulos and colleagues observed that
within the immediate 12 hours following Coronary
Artery Bypass Surgery, 100% of their study population
(n = 2,615) had clinical signs and symptoms consistent
w i t hS I R S .T h i sS I R Sr e s p o n s ei sa l s ok n o w nt oo c c u r
post-operatively following other types of major proce-
dures [3,4]; however, only in cardiac surgical patients
has this uniformity of response been demonstrated in
the intensive care setting.
If infection is suspected in addition to SIRS presenta-
tion, the term sepsis is applied [5,6]. This condition is
the leading cause of mortality in the adult intensive care
unit (ICU), ranging from between 18 to 50% [7-9]. In
developed countries, the incidence of sepsis is expected
to rise due to aging populations, immune-compromised
patients, increasing longevity of patients with chronic
diseases, antimicrobial resistance, especially in younger
people, as well as viral illnesses such as AIDS.
Recent research has suggested that, owing to the
amount of cellular necrosis from major physical injury
and trauma, mitochondrial DNA is released into the cir-
culation, where it is capable of eliciting inflammatory
signals, also referred to as damage (or danger)-asso-
ciated molecular patterns (DAMPs) [10]. It is these
DAMPS (which are also contributed to by nuclear DNA,
purine metabolites, as well as other nuclear and cytoso-
lic proteins), that stimulate an acute phase response by
the innate immune system which is biologically concor-
dant with pathogen-associated molecular patterns
released during infection. Furthermore, the presence of
DNA anywhere other than the nucleus or mitochondrial
nucleoids elicits a response mediated by toll-like recep-
tor-9 and DNA-dependent activator of interferon regu-
latory factors (DAI), resulting in the activation of the
innate immune response, and can also be associated
with the generation of autoantibodies and immune com-
plexes [11]. Thus, following major physical trauma or
other pathophysiological processes that result in cell
lysis en masse, the immune system reacts in a similar
manner to that which occurs when sterile tissues
become infected. Moreover, the findings from Zhang et
al. [10], demonstrate the difficulty in separating infec-
tious from non-infectious SIRS when the innate immune
system responds similarly to both conditions.
For many decades, the cornerstone of sepsis diagnosis
and treatment has been identifying the causative circu-
lating pathogen and quantitating single immune-related
blood analytes – medical determinants which are not
necessarily specific to sepsis, but routinely evaluated to
assess the patient’s physiological response to the patho-
gen. In contrast, it has recently been proposed by
Hotchkiss et al. [12], that the sepsis condition is multi-
factorial and inclusive of the both an early exuberant
innate immune response (or “hyperinflammation”)f o l -
lowed by a stage of protracted immunosuppression that
is referred to as immunoparalysis [12-14]. While this is
still conjecture, there would appear to be a combination
of phases involved in septic episodes that are not neces-
sarily assessable in terms of presentation, physiology,
chemistry, or pathogen load. Given that the immune
response to sepsis is complex and difficult to evaluate
with single analytes, high throughput technologies such
as multiplex PCR have substantive utility for the clinical
development of a diagnostic test that is capable of evalu-
ating perturbations in circulating gene expression pro-
files, and thus determining the status of the patient’s
immune system.
Thus, as the majority of patients admitted to the ter-
tiary care ICU setting have undifferentiated SIRS, it is
of great clinical importance that those patients who
have a suspected infection or are at high risk of infec-
tion can be identified early, in order to initiate evi-
dence-based and goal-orientated medical therapy.
Hence, the primary objective was to validate a molecu-
lar biomarker signature identified ap r i o r ifrom
pre-clinical research by determining performance out-
comes, in a population of critical care patients that
included post-operative surgical patients and blood
culture-positive sepsis patient.
Materials and methods
Study design and research governance
This was a multi-centre, prospective, observational clini-
cal trial conducted across four tertiary critical care set-
tings in Australia from November 2007 to November
2009. Athlomics Pty Ltd sponsored the trial and has
registered this product as the SeptiCyte
® Lab test. The
sponsor initiated and designed the trial in collaboration
with clinical investigators. The study protocol was
approved by institutional review boards (IRBs)/Human
Research Ethics Committees (HRECs) from Mater
Health Services (MHS), Uniting Care, the Royal
Brisbane & Women’s Hospital and the Nepean Hospital
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ment of study volunteers. Independent clinical research
organisations contracted by the sponsor were responsi-
ble for the monitoring and management of clinical data
including verification with source notes.
Data collected from the aforementioned clinical trial
were used to perform microarray studies in which to
define a gene set in which to focus MT PCR studies.
Following, an ap r i o r ipanel of gene expression biomar-
kers was applied to MT PCR data from the clinical trial
to create a diagnostic rule. The MT PCR data were
randomly partitioned into a training set and a test set.
The diagnostic rule was generated from the training set,
and then applied to the test set, in a blinded fashion.
MT and GS performed bioinformatics and statistical
analyses in accordance with details presented in the
study protocol and statistical analysis plan.
Study population and criteria for inclusion and exclusion
All study participants were 18 years or older, had a body
mass index < 40, and provided written informed con-
sent. Patients were recruited as being likely to enter the
Sepsis cohort if they met the ACCP/SCCM Consensus
Statement [6], and had a clinical suspicion of systemic
infection based on microbiological diagnoses. A defini-
tive diagnosis of sepsis was unlikely to be known at the
time patients were enrolled in the study; thus confirma-
tion of sepsis and assignment of patients to the sepsis
cohort was made retrospectively.
Potential sepsis participants admitted to the ICU and,
patients admitted for planned major open surgery, were
excluded from the study if they had any systemic immu-
nological disorders including Systemic Lupus Erythro-
matosus, Crohn’s disease and Insulin-Dependent
Diabetes Mellitus (Type 1 diabetes); were transplant
recipients or were currently receiving chemotherapy
treatment for cancer.
Twenty-seven blood culture positive sepsis patients
with community-acquired infections were enrolled into
this clinical trial as soon as practicable, on admission to
the ICU. Specifically, sepsis patients’ were enrolled
within 24 hours of admission and on average, were in
the ICU for five days. Participants in the post-surgical
(PS) cohort were recruited pre-operatively and blood
samples were collected within 24 hours following sur-
gery (n = 38). Furthermore, 20 healthy adult control
(HC) participants were recruited within the Mater Adult
Hospital staff, on the basis that they had no concurrent
illnesses at the time of blood collection or any past his-
tory of immunological dysfunction. All participants or
their surrogate decision-maker provided written
informed consent prior to the collection of any study
data or biological samples.
Collection of data
Demography, vital signs measurements (blood pres-
sure, heart rate, respiratory rate, tympanic tempera-
ture), haematology (full blood count), clinical
chemistry (urea, electrolytes, liver function enzymes,
blood glucose) as well as microbial status were
recorded. Blood was drawn into minimally two PAX-
gene (PreAnalytix, Feldbachstrasse, Hombrechtikon,
Switzerland) tubes (5 ml total) for gene expression
analyses using the SeptiCyte Lab test.
Gene expression assays
RNA isolation was performed using PAXgene Blood
RNA kits (PreAnalytix, a Qiagen/BD Company, Feld-
bachstrasse, Switzerland) and following standard instruc-
tions recommended by the manufacturer. RNA quality
was determined using an automated electrophoresis sta-
tion (Experion, BioRad (Gladesville, New South Wales,
Australia) and BioAnalyser, Agilent (Forest Hill, Vic-
toria, Australia). The 260 nm/280 nm ratios for all sam-
ples were > 1.9. Once total RNA was extracted, gene
expression was assessed using the Affymetrix HGU133
Plus 2.0 GeneChip
® (Santa Clara, CA, USA) and MT-
PCR SeptiCyte Lab assay.
Microarray studies were conducted on total RNA
extracted from a subset of participants that included 20
HC, 11 post-surgical and 10 sepsis samples, using
HGU133 Plus 2.0 GeneChips (Affymetrix, Santa Clara,
CA, USA). Of the 145 gene expression biomarkers
derived from the early sepsis equine model, 408 probe-
sets were derived. This panel was selected because it
had been demonstrated a priori to contain information
relevant to the separation of the three groups. In brief,
10 μg of total RNA was processed using the 3’ Amplifi-
cation One-Cycle Target Labelling kit (Affymetrix) and
20 μg of generated cRNA was injected into a GeneChip
cartridge. The GeneChip array was incubated at 45°C
for minimally 16 hr in a rotating oven at 60 rpm. Gene-
Chips were then washed and stained with Streptavidin
Phycoerythrin, using Affymetrix supplied wash protocol,
EukGE-Ws2v5.
HGU133 fluorescent images were acquired in a Gene-
Chip
® Scanner 3000 7G (Affymetrix). Affymetrix Power
Tools, R and Perl scripts were used to filter background
n o i s ea n dn o r m a l i s ed a t ab a s e do nad e t e c t i o nm e t r i c
used to identify perfect match probes relative to other
background probes. Differentially expressed genes were
compared if the signal was > 100 and the fold change
was > 2.0. All HGU133 Plus 2.0 GeneChip data are
available from the GEO repository (GSE28750).
The MT-PCR approach first described by Stanley and
Szewczuk [15] combines reverse transcription and preli-
minary amplification within Step 1 followed by final
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prepared that contained in part, lyophilized primers for
Step 1 of this method and 10 ng of RNA template. Pri-
mer sets were designed by AusDiagnostics Pty Ltd (Syd-
ney, NSW, Australia), and validated for clinical
performance by Mater Pathology. Inner or nested ampli-
cons were approximately 70 to 90 base pairs (bp) and
the outer amplicons were up to 150 bp. All primers
spanned intron-exon boundaries and were preferentially
designed toward the 3’ end.
In this reverse transcription and amplicon enrichment
stage, reactions were performed using 20 ul volumes
consisting of 10 ul of Step 1 mastermix, 8 ul of molecu-
lar biology grade (diethylpyrocarbonate) water, and 2 ul
of RNA template (minimally 10 ug). Final target amplifi-
cation process of multiplexed amplicons (Step 2), uti-
lised involved preparation of the following PCR mix: 10
ul of the Step 1 reaction, was added to 550 ul of DEPC
w a t e ra n d5 6 0u lo fM a s t e r m ix. Twenty microliter ali-
q u o t so ft h i sS t e p2P C Rm i xw e r et h e na d d e dt ot h e
corresponding gene disk containing the lyophilized
inner or nested primers. Amplification was performed
on the RG6000 (Qiagen) thermal cycler.
Gene expression levels, expressed as “relative fold
change”, were determined using a method comparable
to the 2
-ΔΔCt method described by Pfaffl [16], where the
point of peak cycling acceleration was extrapolated to
represent maximum fold change. JAG1, FUK and
PRDM8 were used as normalisation control genes in the
calculation of gene expression fold changes. Five nega-
tive controls (using DEPC water as a template), and five
positive controls (using commercially available Universal
RNA as a template) were included as references.
Bioinformatics and statistical analysis of data
Four multi-feature classifiers were used to separate HC
versus Mixed Inflammation (MI included both PS and
sepsis groups), as well as PS Vs sepsis using the
HGU133 Plus 2.0 gene expression data. These classifica-
tion techniques include Recursive Partitioning, Figueire-
do’s method, the “least absolute shrinkage and selection
operator” or LASSO, and Logistic Regression on Princi-
pal Components. In particular, the first three of these
four classifiers were applied as they have the capacity to
identify small subsets of biomarkers using a high
‘throughput’ platform. Individual genes were examined
using an empirical Bayes adjusted linear model [17],
with P-values adjusted for multiple comparisons using
Holm’s method [18].
In the absence of a formal ‘validation set’ of samples
in which to apply the algorithm created from the ‘train-
ing set’ of data, the Leave-One-Out Cross Validation
technique was used. To estimate the error rate using
t h i st e c h n i q u eas a m p l ef r o mt h eo r i g i n a ls e tw a s
removed, the method rebuilt using the same procedure
as before (including re-running of the pre-selection
step), and this model used to predict the ‘left out’ sam-
ple. This is repeated so that each sample is sequentially
left out, and the error rate computed in its absence.
To further validate the microarray data, the SeptiCyte
Lab signature was applied to all currently available Gene
Expression Omnibus (GEO) HGU133 Plus 2.0 Gene-
Chip data derived from human whole blood leucoctye-
based gene expression studies. The GEO database is an
international publicly available archive of GeneChip data
that can be used in research and development, for inter-
rogation of proprietary gene signatures to support
assessments of diagnostic utility. Following a review of
this public database, an additional set of controls (n =
164) with no known systemic inflammatory or immuno-
logical conditions were added to the microarray study
cohort.
For the MT-PCR analyses, a panel of maximally 42
genes (also known as SeptiCyte Lab) was used to gener-
ate a diagnostic classifier using a LogitBoost machine
learning algorithm [19]. The data were randomly parti-
tioned into a training and validation set. The LogitBoost
algorithm was used on the training set, to generate a
classifier. The classifier was then applied to the valida-
tion set. Posterior probabilities of each condition were
obtained for the validation set. These posterior probabil-
ities were used as a diagnostic index, and the diagnostic
performance was assessed using a receiver operator
characteristics (ROC) curve [20,21]. After the initial area
under the ROC curve was calculated the procedure was
repeated, such that the data were randomly partitioned
500 times into training and validation sets, and the ROC
area calculated for each random partition. The proce-
dure was also conducted to include a random permuta-
tion of group labels in the training and validation sets.
The distribution of ROC areas was calculated under this
permutation scheme.
It should be noted that no tabulations of sensitivity or
specificity have been provided, since these parameters
have meaning only in the context of a well-defined clini-
cal population, where the population has been sampled
more extensively than that described in this study.
Furthermore, sensitivity and specificity may always be
traded, that is, specificity may be increased by reducing
sensitivity or vice versa. Thus, meaningful claims about
sensitivity and specificity can only be made in late-stage
clinical research, when the diagnostic thresholds have
been established using large cohorts of blinded samples.
Results and discussion
Pre-clinical research using a novel equine model of sep-
sis was designed to examine the innate and adaptive
immune responses. In brief, endotoxemia and sepsis was
Sutherland et al. Critical Care 2011, 15:R149
http://ccforum.com/content/15/3/R149
Page 4 of 11induced in a cohort of foals (n = 12) after animals were
administered a high carbohydrate diet for 48 hours
causing damage to the lining of the intestine and allow-
ing live and dead bacteria to invade the bloodstream,
resulting in bacteremia and multiple organ dysfunction.
Given recent findings reported by Wade and colleagues
[22], where it was demonstrated that 53% of equine
chromosomes show conserved synteny to a single
human chromosome, this suggests that the horse gen-
ome has strong concordance with that of the human
and, validates this model as an appropriate one for clini-
cal research and development. Furthermore, based on
these pre-clinical findings, a complete clinical research
program was developed in order to establish the
utility of the biomarkers for the early diagnosis of sepsis
(Figure 1).
From these studies, 145 human white blood cell
(WBC) genes associated with acute infection and inflam-
mation were identified as being abnormally expressed
both in the equine and human contexts. Following, a
panel of 42 genes were identified a priori using pre-clin-
ical research outcomes from the pre-clinical results.
This panel of biomarkers has been primarily linked with
innate and early adaptive immune function/activation
pathways, including those governing cell cycling and
growth, WBC differentiation, extracellular matrix remo-
delling, and immune modulation (Figure 2). Based on
the physiological response to infection, that is, monocy-
tosis, neutrophil activation, monocyte-macrophage
differentiation, extravasation, as well as cell-mediated
responses, these patented markers appear to characterise
a large cross-section of early immune behaviour. We,
therefore, developed a clinical research program to vali-
date this novel biomarker panel to determine its efficacy
as a diagnostic test for the separation of sepsis within an
inflammatory milieu.
A total of 85 participants were enrolled in this study
to be assessed for sepsis status using a gene expression
biomarker test (SeptiCyte Lab). The baseline characteris-
tics between the PS and sepsis cohorts were comparable
in terms of age, sex and ethnic background; however,
while demographic variables were well matched between
the healthy control (HC) and in-patient groups, the HC
were significantly younger (Table 1).
Of the surgical in-patients enrolled into this study, 19
had major open cardiac surgery that included CABG,
pericardiectomy, valve replacement and atrial septal
defect closure procedures. A further 14 participants had
major thoracic procedures that included pleurodesis,
lung wedge resection with and without lung volume
reduction, lung lobectomy and pulmonary decortication.
Lastly, five participants underwent major open vascular
and neurosurgery that included AAA repair, aortic, iliac,
femoral and femoral-popliteal endarterecetomy proce-
dures, as well as stereotactic removal of a cerebral
lesion, respectively. Based on routine clinical catheter tip
culture monitoring, none of these participants had any
evidence of infection during, or after their participation
in this trial; however, all of these surgical in-patients
were minimally on broad-spectrum prophylactic antibio-
tic therapy at the time of the study blood collection.
Of the 27 patients recruited into this trial who met
the criteria for sepsis, and who had evidence of systemic
infection, 14 had microbiological findings consistent
with a gram-positive infection, 11 had findings consis-
tent with a gram-negative infection, and 2 had findings
of both gram-negative and gram-positive infections. As
this was an observational clinical study, all sepsis partici-
pants were treated as per clinical guidelines regardless of
SeptiCyte Lab results. On average, the sepsis partici-
pants’ stayed in the ICU for five days.
In preliminary microarray investigations, HGU133
Plus 2.0 GeneChips demonstrated that signatures for
HC, PS and sepsis were well separated when visualised
using a Principal Component Analysis (Figure 3A). The
area under the curve (AUC) for the ROC curve, using
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Figure 1 A schematic of SeptiCyte lab development.S u m m a r y
of the development pathway of the SeptiCyte Lab test from high
throughput pre-clinical gene expression interrogation in an equine
sepsis model through to clinical evaluation on a more dynamic
platform better suited to the assessment of smaller biomarker
panels.
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for the detection of sepsis. To evaluate the robustness of
this gene expression signature, GEO control samples
were compared with gene expression data from the sep-
sis and HC cohorts. In Figure 3B a strong separation
was observed between all ‘controls’ (GEO and HC)
when compared with the sepsis cohort, thus generating
a specificity of greater than 99% using ROC curve
analyses.
The objective of the GEO data exploration was to
investigate whether or not the diagnostic signature is
robust to inter-laboratory variation. There is limited evi-
dence that the signature is robust, but inter-laboratory
variation in positive sepsis samples would have to be
evaluated before this can be proven. Importantly, the
high specificity for the GEO data must be interpreted
with caution given that no sepsis data from the GEO
database were included. Whilst the GEO database does
contain gene expression information from sepsis trials,
the clinical status of the participant cohorts appeared to
be ambiguous based on Inclusion and Exclusion Criteria
and for this reason, it was not included in these
analyses. At this stage it may be the case that the very
high specificity is adversely affecting sensitivity. How-
ever, it is encouraging that a classifier developed in one
laboratory does not result in a large number of false
positives when applied to samples from a large number
of laboratories. This provides some evidence that the
difference between sepsis and control patients from this
trial is greater than the inter-laboratory variation in the
gene expression data. Had the difference between con-
trol and sepsis patients from the current trial been small
with respect to between laboratory variations in ‘control’
gene expression, it is likely to have resulted in the GEO
data decreasing the sensitivity. In this sense, the GEO
data provide preliminary evidence that the sensitivity of
the test is robust to inter-laboratory variation.
It is routine practice in research and development that
microarray studies be employed in preliminary investiga-
tions, particularly in molecular oncology, in order to
identify statistically relevant panels in which to re-evalu-
ate and further refine in the clinical setting [23-25].
Given that these analyses were not restricted to inflam-
matory biomarkers, these results provided a strong
rationale for further clinical research.
When the ap r i o r iset of 145 biomarkers was
compared with all gene expression change from the
Affymetrix Genechip data they were strongly representa-
tive of widespread change and, had the greatest capacity
to differentiate within the MI cohort. Thus, based on
preliminary outcomes, a further subset of 42 biomarkers
including three control/normalisation genes were tested
in a larger cohort of critical care patients, to ascertain
the clinical utility of this sepsis test using the more
efficient quantitative real time PCR platform.
Following MT-PCR data extrapolation, comparisons
were first made between HC and generalised systemic
inflammation and wounding (MI). Findings from these
analyses indicate, based on area under the curve (AUC)
for ROC curve, that the ability to accurately detect
severe systemic inflammation was approximately 92%
using the full gene panel (Table 2). Based on further
posterior probability analyses that were conducted using
algorithms for 42 and 7 gene expression biomarkers
(Figure 4A, C), this result was determined to be
statistically significant (P < 0.002) in a permutation test.
Furthermore, to demonstrate that there was no underly-
ing bias in the patient population, the HC and MI
cohorts had classifiers removed and were randomly
mixed during posterior probability analyses, indicating
that diagnostic performance (by chance) was approxi-
mately 0.5 (Figure 4B, D).
Secondly, the mixed inflammatory cohort was split
into PS and sepsis, where AUC ROC permutation
r e s u l t sf o rt h ef u l lg e n es e t( n = 42) and a sub-set
Figure 2 Composition of gene expression biomarkers in the
SeptiCyte Lab test. Based on longitudinal sampling in pre-clinical
trials using an equine sepsis model, molecular biomarkers related to
genes directly involved in innate and early adaptive immune
function, cell cycling, differentiation, extracellular remodelling, as
well as immune modulation.
Table 1 Baseline characteristics of the study population
Characteristic HC (N =
20)
Sepsis (N =
27)
PS (N =
38)
P-
value*
Age-yr
Mean 38 60 68 NS
Range 21 to 60 38 to 82 51 to 86 NS
Male sex – % 50 55 64 NS
Caucasian –
%
100 94 100 NS
* Statistical comparisons made between Sepsis and PS
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between 86 and 92% (P < 0.002), as displayed in Figure
5A, C. Again, when participant classifiers were removed
for the purpose of posterior probability analyses,
random diagnostic performance was on average 0.5
(Figure 5B, D).
Interestingly, when small sets of gene expression
markers are used, the performance of the algorithm to
accurately detect sepsis remained high. In fact, several
sets of seven biomarkers were evaluated, and perfor-
mance remained high for each set, suggesting that there
is substantial redundancy in the 42-biomarker set.
Despite this redundancy, the SeptiCyte Lab will continue
to include all 42 biomarkers for future studies designed
to evaluate sepsis status in patient populations from dif-
ferent settings such as: in neonatology and paediatrics
settings, patients who are immune-compromised follow-
ing chemotherapy, as well as in mixed ethnic popula-
tions. The larger biomarker set provides a higher chance
of success for these more diverse populations.
Quantitative real time PCR, also referred to as the
MT-PCR method in this paper, is a fast and efficient
platform on which to conduct gene expression studies,
and an ideal platform for use in a tertiary care clinical
pathology unit. Given the current level of automation,
and the requirement for as little as 10 ng of RNA (< 1
PAXgene or EDTA blood sample), test results can be
reported back to the referring clinical team within three
hours. Hence, there is the capacity to substantively
improve early clinical management plans when consider-
ing it may take between 48 and 72 hours for blood
culture results to become available, a limitation that is
further exacerbated by the failure to grow an organism
in a high percentage of blood cultures taken from
patients who have been deemed to be extremely likely
to have sepsis on clinical grounds.
To date, the application of such a highly multiplexed
gene expression test for the early detection of sepsis is
unique; however, there are similar diagnostic products
on the market for other immune-related conditions in
the field of heart-lung transplantation [26]. Importantly,

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Figure 3 Principal Component Analysis for preliminary HGU133 Plus 2.0 array studies. A strong separation between HC (referred to as
“Control”) and MI groups and a moderate separation between PS and sepsis participants was noted (A), where all but one sepsis sample is
below the PS threshold. Moreover, when GEO control samples were included in these analyses, control gene expression profiles were largely
independent of the sepsis group (B).
Table 2 AUC ROC results comparing diagnostic
performance between control and various clinical cohorts
Comparison Biomarker Set Mean SD‡ P-value*
MI Vs HC 42 0.921 0.0568 < 0.002
MI Vs HC 7 0.862 0.0640 < 0.002
Sepsis Vs HC 42 0.938 0.0557 < 0.002
Sepsis Vs HC 7 0.910 0.0479 < 0.002
PS Vs HC 42 0.891 0.0687 < 0.002
PS Vs HC 7 0.833 0.0661 < 0.002
Sepsis Vs PS 42 0.921 0.0568 < 0.002
Sepsis Vs PS 7 0.862 0.0640 < 0.002
‡ Standard Deviation; *Statistical significance is assumed when P < 0.05.
Based on 500 random permutations the minimum possible P-value is < 0.002
§H C– Healthy Control; MI – Mixed Inflammation; PS-Post Surgical
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Page 7 of 11multi-marker diagnostics may provide guidance where
there is nonlinearity of data, a situation commonly asso-
ciated with complex disease states.
In terms of limitations, this test currently has the
capacity to distinguish between normal individuals
(healthy controls) versus those with systemic inflam-
mation of unknown aetiology (MI), as well as PS
inflammation (surrogate SIRS) and sepsis (confirmed
bacteraemia). However, as indicated there are a num-
ber of ‘high risk’ populations that develop infection
due to immunomodulating medications used following
transplantation, chemotherapy regimens and manage-
ment of autoimmune diseases. To use this test effica-
ciously in such complex cases would require baseline
gene signatures for these populations. Further studies
are underway to derive these.
Conclusions
In summary, these findings demonstrate that this novel
gene expression biomarker test (SeptiCyte Lab) has the
capability, based on diagnostic performance outcomes,
to accurately detect early evidence of sepsis well before
the availability of microbiology results. Current clinical
research will further investigate the efficacy of this
assay to provide guidance on the host immune
response via the monitoring of severe sepsis patients,
as well as to provide diagnostic information on other
‘at risk’ groups such as post-operatively following
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Figure 4 AUC ROC permutation comparisons and distribution graphs between mixed inflammation and Healthy Control cohorts.
A and B display results for the AUC ROC following 500 iterations using the full gene set and distribution results when cohort labels are
removed, respectively. In C and D this analysis was repeated using a diagnostic signature that is operating with a set of seven genes, where
minimal change in performance was noted.
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Page 8 of 11major surgery and patients with chronic immune
incompetence.
Key messages
￿ Using results from an equine sepsis model, 42
genes were selected ap r i o r ito test a novel gene
expression panel using biomarkers associated with
innate and early adaptive immune function, cell
cycling and growth, WBC differentiation, extracellu-
lar remodelling and immune modulation.
￿ Preliminary microarray studies using a PCA sug-
gests that the detection of sepsis in a group of HC,
PS and sepsis patients was > 95%, a finding that
increased to > 99% when further GEO control data
were included in the analysis.
￿ MT-PCR data analysed using multi-classifier tech-
niques, demonstrated that the average area under
the ROC curve for sepsis detection was approxi-
mately 92% (P < 0.02), in a mixed inflammation
group (post-surgical and sepsis patients).



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Figure 5 AUC ROC permutation comparisons and distribution graphs between PS and Sepsis cohorts. Permutation analyses were
conducted using 500 iterations, where the data was randomly split into training and validation sets to evaluate diagnostic performance. Average
AUC ROC for gene sets of 42 and 7 were determined to be 0.92 ± 0.0586 and 0.862 ± 0.0640, respectively. When labels associated with cohort
status were removed, the AUC distribution was on average 0.498 indicating that there was no inherent bias in this methodology.
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Page 9 of 11￿ Applying a sub-set of gene expression markers (n
= 7), the average area under the ROC curve for sep-
sis prediction in a mixed inflammation group was
approximately 86% (P < 0.02).
￿ Based on overall outcomes, these findings suggest
that this sepsis gene expression test is robust;
ongoing studies will determine whether it performs
equally well when applied to different patient popu-
lations and ethnic groups.
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